Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Di Bartolomeo M;Niger M;Morano F;Corallo S;Antista M;Tamberi S;Lonardi S;Di Donato S;Berardi R;Scartozzi M;Cardellino GG;Di Costanzo F;Rimassa L;Luporini AG;Longarini R;Zaniboni A;Bertolini A;Tomasello G;Pinotti G;Scagliotti G;Tortora G;Bonetti A;Spallanzani A;Frassineti GL;Tassinari D;Giuliani F;Cinieri S;Maiello E;Verusio C;Bracarda S;Catalano V;Basso M;Ciuffreda L;De Vita F;Parra HS;Fornaro L;Caporale M;de Braud F;Pietrantonio F

2019-01-01